Research · End-stage options

End-stage options: fusion, replacement, total talus

Fusion, ankle replacement and total talus replacement. Revision hazard doubles under age 55, and the FDA has told surgeons to prefer other implants over one of them. The far end, not the plan.

Total Ankle Arthroplasty (TAA) vs. Ankle Fusion

Meta-Analysis Summary (4,312 TAA, 1,091 fusion procedures)

FDA Safety Communication: One Ankle Replacement Implant Is Failing More Than Expected

→ “Ankle replacement” is not one product. In June 2026 the FDA told doctors to prefer other options over one specific implant, because long-term registry data showed it failing at roughly twice the rate of its competitors. This is not a recall, and it is not about ankle replacement in general.

Recorded July 28, 2026. The FDA notice itself is dated June 3, 2026 — outside this week's window, but it had never been captured on this page. The FDA issued an update to an earlier safety communication about the Hintermann Series H3 Total Ankle Replacement (DT MedTech LLC, previously sold as Hintegra by NewDeal/Integra), approved in the US in 2019 with mandated post-approval studies [246]. Three independent data sources:

FDA's recommendation to surgeons is to “consider using an available alternative treatment option where possible.” The device has not been recalled and remains on the market. For anyone already implanted and doing well, the FDA explicitly does not recommend removal — only continued follow-up, with CT rather than X-ray if a fractured plastic component is suspected, because the finding can be subtle.

Why this is on this page. Total ankle replacement sits at the far end of the decision tree here and is not close to being on the table. It matters for two reasons anyway. First, it is a concrete reminder that implant choice within a category can matter as much as the choice between categories — a nearly two-fold difference in revision risk between devices dwarfs most of the differences being weighed between procedures. Second, the failure mode was only visible in fifteen-year registry data, which is longer than most of the follow-up cited anywhere else on this page. For a patient in his thirties, that is the relevant timescale, and it is a reason to ask specifically which implant a surgeon uses and what its registry record looks like — not merely whether replacement or fusion is better in general.

2024-2025 TAA Advances

Recent studies show significant improvements in newer implant designs [86]:

TAA in Young Patients (<50-55 years)

93.5%
Survival (<50 yrs) [56]
94%
Survival (<55 yrs) [57]
1.8-2.65x
Higher revision risk [56]
91.8%
10-yr implant survival [58]

Third-generation designs show improved results vs older prostheses. At medium-term, TAA is at least as effective in patients <50 as in older patients [59].

2025 National Registry Data

Recent national registry analyses provide large-scale outcome data [88]:

2026 Landmark: 25-Year, 41,000-Patient Registry (England)

The largest-ever comparison of TAR vs ankle fusion (10,335 TARs vs 30,704 fusions, 1998-2023) [172]:

2.73x
TAR revision hazard vs fusion
35%
TAR 25-year intervention-free survival
69.2%
Fusion 25-year intervention-free survival

→ This registry endpoint was later adjacent-joint fusion. It does not exclude adjacent-joint degeneration, pain, or other symptoms after ankle fusion.

Ankle Fusion Long-Term Outcomes

2024-2025 Arthrodesis Techniques

Newer fusion techniques show improved outcomes [89]:

Conversion: Fusion to TAA

For painful fusions, conversion to TAA is possible [62]:

Key point: All doctors agreed ankle fusion should be avoided for someone young with good ROM. Cleveland Clinic noted TAA would be a later escalation step.

Total Talar Replacement (TTR)

Total talar replacement is a newer procedure where the entire talus bone is removed and replaced with a custom 3D-printed prosthetic implant. Because the talus has no direct muscle/tendon attachments and limited blood supply, it is uniquely suitable for full bone replacement.

→ Unlike total ankle replacement (TAR) which replaces the joint surfaces of both the tibia and talus, TTR replaces only the talus bone itself. TTR is indicated when the talus is too damaged for cartilage repair (AVN, collapse, large cystic defects unresponsive to treatment).

The Procedure

FDA Approvals

Device-Specific Indications and Contraindications

→ “Total talar replacement” is not one product — the FDA labeling differs by implant, and so does who actually qualifies.

Outcomes Data

Systematic review of 22 studies (191 patients, 196 tali) [162]:

94.5%
Implant survivorship [159]
69.6%
Significant functional improvement [162]
0.1%
Cumulative implant failure rate [162]
8.2 → 2.1
VAS pain score (titanium series) [163]

Additional clinical results:

TTR vs. Ankle Fusion vs. TAR

Longevity: The "Every 10 Years" Question

Dr. Salk stated the implant would need replacing approximately every 10 years. What the data shows:

→ The "every ~10 years" figure should be treated as a surgeon estimate or extrapolation, not a proven lifespan for current patient-specific TTR implants. The only genuine long-term follow-up is the Japanese ceramic series (Morita 2022, 10+ years), and modern 3D-printed cobalt-chrome and titanium designs still have only short-term to mid-term follow-up.

Risks and Complications

TTR is encouraging, but it is not a “drop-in replacement bone” with trivial downside. The specific rates from the two largest modern cohorts are sobering:

2026 Regulatory Status Updates

Two practical regulatory updates that materially affect how TTR should be interpreted today:

→ Translation: the “broad OLT-indication” TTR option in the U.S. currently rests on a single active device (restor3d) whose post-market evidence base is barely off the ground, while the other recently approved U.S. talar replacement (4WEB) may not be commercially available at all.

Evidence Gap for Raymond’s Exact Situation

The published TTR evidence does not match Raymond’s case especially well:

There is no strong peer-reviewed TTR series specifically for a failing focal talar allograft/OLT with otherwise preserved joint space. Direct evidence for Raymond’s exact use case is still thin.

Added August 3, 2026 — what the FDA adverse-event database shows, and it is the clearest argument on this page

→ The published series report how patients did. The adverse-event reports show what happens when it goes wrong — and the pattern is that each revision costs another joint.

A report filed with the FDA in June 2026 describes the escalation ladder run to its end. Quoted verbatim: “The patient had a talus fracture nonunion with previous talar replacement with deformity and advancing arthrosis. Patient has had two revisions from a total talus to a total talus with total ankle and subtalar fusion. Now, physician is revising again with spherical-bottom talus with total ankle and STJ and TN fusion” [322]. That is a fourth talus construct, and the sequence is the point: talus alone, then talus plus total ankle plus subtalar fusion, now adding talonavicular fusion. The hindfoot is being spent one joint per revision.

Two further reports, both filed in June 2026, describe custom talus implants explanted at roughly six and six-and-a-half years. One: “joints around the implant eroded causing the implant to shift out of position.” The other: the patient “presented with arthritis in the subtalar and talo-navicular joints” [323]. Degeneration of those neighbouring joints is precisely what the device labels list as a contraindication to implanting in the first place — and these reports show the implant producing it. Corrected August 4, 2026: this passage previously described that six-year interval as close to how long this patient’s own 2012 allograft lasted. It is not — the allograft ran from October 2012 to March 2025, about twelve and a half years. These implants were explanted in roughly half that time, which makes the comparison less reassuring rather than more. A third 2026 report records explant at three months for wound-closure failure, replaced with an antibiotic spacer; and a cluster of five post-approval study reports includes complex regional pain syndrome at ten months and two anterior wound dehiscences within a month of surgery.

State the limits honestly. There are only eighteen such reports in total across all years, every manufacturer concluded that no device defect was involved, and adverse-event counts cannot be converted into rates without denominators that do not exist for humanitarian-exemption devices. One of these reports describes an event from February 2023 filed forty months later. None of this says the operation usually fails. What it does is put a mechanism behind the framing already on this page: total talus replacement is a move that forecloses options rather than preserving them, and at 30 the relevant question is not whether it works but what the second and third revisions cost.

Added August 4, 2026 — a fourth 2026 adverse-event report, and it is the fastest failure yet

One more total-talus report was found this week that previous sweeps missed. A 4WEB custom device was “explanted approximately three months following the initial surgery… tissue closure complications and a delayed wound. The 4WEB device was explanted… and replaced with an antibiotic spacer” [342]. It completes the 2026 picture for this device class: three of the four total-talus adverse-event reports filed in 2026 involve 4WEB implants — one lost at three months to wound failure, two at roughly six and six-and-a-half years to adjacent-joint erosion.

The comparison that matters is with his own history, and it is not close. This patient's 2012 bulk allograft ran from October 2012 to March 2025 — about twelve and a half years. The metal implants in these reports failed at three months and at roughly six years. Dr. Salk's estimate that a talar replacement would need replacing “every 10 years or so” is, against the reported failures, optimistic rather than conservative. None of this converts eighteen adverse-event reports into a failure rate — it cannot, and the limits stated above still apply — but it does mean the durability case for metal over biology is weaker here than it looks, because the biology already delivered twelve years in this exact ankle.

Added August 4, 2026 — the field still cannot say whether fusion or replacement is better

→ Useful mainly as a defence against anyone presenting either operation as the obvious eventual answer.

A review published August 3 compared total ankle replacement against ankle fusion across the 2023–2025 literature [349]. A level II multicentre study found long-term results “similar”; a meta-analysis favoured replacement on patient-reported outcomes; three systematic reviews found comparable outcomes and complication rates, though replacement showed “lower total complications, implant removals, adjacent level fusion surgeries, and non-union” afterwards. The authors conclude that “the existence of mixed evidence… makes it necessary to select the surgical technique… on an individual basis.”

Three honest discounts. It is a narrative review, so there are no pooled numbers. It covers end-stage arthritis, which is precisely where this ankle is not. And it does not stratify by age or by post-traumatic aetiology, so it never analyses the subgroup — under forty, post-traumatic, joint space preserved — that would actually describe him. What it is good for: if a surgeon frames fusion as the inevitable destination, the current literature does not support that being settled. The review also records that “racial/ethnic, socioeconomic, and payer status disparities have been reported in the likelihood of experiencing TAR versus AF” — a reason to ask why a particular option is being recommended.

Added August 13, 2026 — the adverse-event channel reopened after six weeks dark, and its two new reports extend the ladder to its last rung

→ The FDA database that produced every report above had been frozen since late June. It refreshed this week — and the July batch contains the two worst outcomes yet reported for this implant class: one conversion to fusion, and one patient who chose amputation.

The MAUDE dataset refreshed on August 5 (its receive-frontier jumped from June 30 to July 31, closing the 39-day blind spot the sweep logs had been measuring), and the July batch holds two further 4WEB custom total-talus reports, both received July 15 via the manufacturer’s routine annual survey [417]. The first: a total talus implanted in 2024 began to subside; a 2025 revision injected synthetic bone substitute to arrest it; a further 2025 revision explanted the construct entirely and converted to tibiotalocalcaneal fusion with another manufacturer’s spacer. The second, in a patient with pre-existing ankle and subtalar arthritis and talar AVN: the subtalar fusion accompanying the implant was “felt to be unstable and a persistent source of pain and disability” — and the patient elected below-knee amputation, the first amputation outcome anywhere in this device class’s reports.

The tally is now 20 reports all-time for the custom-talus product code, six received in 2026, five of them 4WEB. Every limit stated in the August 3 entry still applies — no denominators, counts are not rates, survey-solicited reports have their own bias — and one report of an elected amputation is an anecdote, not an outcome statistic. But the escalation ladder this page describes — each revision spending another hindfoot joint — previously ended, in the reported data, at “revising again.” It now has documented terminal rungs: conversion to fusion when the implant cannot be held, and amputation when the fusion itself becomes the pain source. That is what “forecloses options” means, written out by the reporting system rather than by this site.

Added August 12, 2026 — what recovery after TATTR looks like when it goes well, from the first published rehab protocol

→ Everything above is about whether and when the operation fails. This is the missing other half: one documented case of what a structured recovery from it looks like.

An Italian rehabilitation group published the first quantified rehabilitation case report after combined total ankle + total talus replacement [412]: a 59-year-old with talar AVN and advanced post-traumatic OA — the classic TATTR indication — went through five months of structured rehab (progressive strengthening, proprioceptive platform training, antigravity-treadmill gait retraining, visual-feedback gait optimization) and moved from Berg Balance 30 → 56, Tinetti 9 → 29, and EQ-5D index 0.169 → 1.0, with postural sway cut by three quarters. It is a single case — it says nothing about rates, durability, or the adverse-event ladder documented above, and a hand-picked publishable recovery is by definition a best case. Its use here is narrow: if this operation ever does become the plan, the recovery is not passive waiting — this names the rehab components a good program included, and shows independent function at five months is at least achievable.

Alternative: Partial Talus Replacement / Talar Hemiarthroplasty

→ Rather than removing the whole talus, this replaces only the damaged dome with a custom metal cap — potentially more anatomically proportional to a focal medial OLT or failed allograft than whole-bone replacement.

The evidence base here is small enough that it should not be presented as established. But it is absolutely worth asking about before accepting whole-talus replacement as the only metal option for a focal medial dome lesion.

Who Is It For?

FDA-approved indications for the restor3d HDE (the broadest U.S. label) include [160]:

Important nuance: In the U.S., broad FDA HDE use of total talus replacement for large cystic talar osteochondral defects is currently device-specific rather than universal. The strongest official regulatory support comes from the restor3d implant, but most published TTR outcome studies still focus on AVN, talar collapse, or trauma rather than failed focal talar allograft. Candidacy also depends heavily on whether the tibiotalar, subtalar, and talonavicular joints remain healthy enough, because degenerative changes in those joints are listed as contraindications in official device labeling. Modern 3D-printed implants have encouraging early survivorship, but secondary surgeries, infection, and adjacent-joint degeneration remain important risks, and true long-term durability is still unknown.

For Raymond: TTR is not the first-line next step for the current situation. The standard algorithm for a focal OLT with preserved joint space places this lesion in the osteochondral allograft / autograft / MACI category. TTR is a real, on-label U.S. option for some large cystic talar OLTs via restor3d — but the published literature is still dominated by AVN, collapse, and trauma rather than failed focal talar allograft, and candidacy depends heavily on the condition of the tibial plafond, subtalar joint, talonavicular joint, and overall alignment. If cystic changes progress to AVN or talar collapse, TTR becomes more clearly indicated. At age 30, the key advantage over fusion is motion preservation; the key risk is that if it fails, salvage options become progressively more limited (primary salvage: TTC fusion). Partial talus replacement / talar hemiarthroplasty is a nearby option that may be more anatomically proportional to a focal medial dome lesion, though its evidence base is very small.

Questions to Ask Dr. Salk